Trials / Completed
CompletedNCT00125944
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | FluMist |
Timeline
- Start date
- 2005-07-01
- Completion
- 2006-01-01
- First posted
- 2005-08-02
- Last updated
- 2007-05-09
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00125944. Inclusion in this directory is not an endorsement.